Systems Biology of Trivalent Influenza Vaccine (TIV) in Young and Elderly

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Nadine Rouphael, Emory University
ClinicalTrials.gov Identifier:
NCT01232868
First received: October 23, 2010
Last updated: May 29, 2014
Last verified: May 2014
  Purpose

Vaccination is the most effective way of preventing infectious diseases. Despite the success of vaccines in general, vaccines induce diminished antibody responses and lower protection in the elderly in particular. This could be explained by a defect in the early responses of an ageing immune system. A better understanding of the basic immunological mechanisms that mediate vaccine efficacy is incomplete. Such information is critical and could greatly decrease both the cost and the time to new vaccine development particularly for the geriatric population.

In this trial, the investigators will study the immunologic differences of an FDA approved licensed influenza vaccine between a younger and an older group. Twenty two healthy volunteers between the age of 25-40 and forty four healthy volunteers above the age of 65 will be enrolled in the study. Each participant in the study will be given one flu shot. Blood work will be obtained prior to vaccination, one day, three days, seven days, fourteen days, as well as one month and six months after vaccination. Throughout the duration of the study, the participants will be monitored for safety.


Condition Intervention
Immunity
Influenza
Biological: trivalent Influenza vaccine (TIV)

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: Systems Biology of Trivalent Influenza Vaccine (TIV) in Young and Elderly

Resource links provided by NLM:


Further study details as provided by Emory University:

Primary Outcome Measures:
  • Number of participants with innate immune signatures that correlate with the level of antibodies after flu shot [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    The primary outcomes will identify the number of participants with innate immunity signatures in the young and older adults after the flu shot. The primary outcomes will also correlate these innate immunity signatures to the levels of antibodies produced after the flu shot.


Secondary Outcome Measures:
  • Number of participants with specific B cell responses that correlate with the innate immune signatures [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    The secondary outcomes will identify the number of participants with a positive B cell response to the flu shot particulary looking for antibody responses, presence of plasmablasts, antibody repertoire.


Enrollment: 66
Study Start Date: October 2010
Study Completion Date: October 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Age 25-40
Trivalent Influenza vaccine given to age 25-40
Biological: trivalent Influenza vaccine (TIV)
0.5 ml IM as a single dose in a prefilled syringe.
Other Name: Fluzone
Age ≥65
Trivalent Influenza vaccine given to age≥65
Biological: trivalent Influenza vaccine (TIV)
0.5 ml IM as a single dose in a prefilled syringe.
Other Name: Fluzone

Detailed Description:

RATIONALE:Trivalent Influenza vaccine (TIV) is known to induce diminished functional antibody responses and lower protection in the elderly. Here we hypothesize that this is due to intrinsic defects in innate responses which translates into suboptimal Hemagglutination Inhibition Assay (HAI) titers. Therefore, early innate signatures of vaccination should correlate with, and predict the immunogenicity of TIV in the young and elderly.

STUDY DESIGN: Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic adverse events (AEs) from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw.

Additionally, only AEs considered related (unlikely, possibly, probably or definitely related) will be collected and reported in this study from Day 0 (vaccination) to Day 180. After Day 30 only related SAEs will be collected and reported.

  Eligibility

Ages Eligible for Study:   25 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy individuals aged 25-40 years, or ≥65 years old.
  2. Able to understand and give informed consent.
  3. Women of child-bearing potential (not surgically sterile via tubal ligation, bilateral oophorectomy or hysterectomy or who are not postmenopausal for ≥1 year) must agree to practice adequate contraception that may include, but is not limited to, abstinence, monogamous relationship with vasectomized partner, barrier methods such as condoms, diaphragms, spermicides, intrauterine devices, and licensed hormonal methods for 30 days before and 30 days after trivalent Influenza vaccination.

Exclusion Criteria:

  1. Receipt of immune products:

    • Receipt of blood products 3 months prior to study entry or expected receipt through 6 months after study entry
    • Receipt of any live virus vaccines within 4 weeks prior to study entry or expected receipt within 4 weeks after study entry*
    • Receipt of any inactivated vaccine within 2 weeks or expected receipt within 2 weeks after study entry*
    • Receipt of the 2010-2011 influenza vaccine
  2. Documented influenza infection during the 2010-2011 influenza season. Not excluded from the study, volunteers with prior upper respiratory infections during the 2010-2011 influenza illness.
  3. Presence of co-morbidities or immunosuppressive states such as:

    • Chronic medical problems including (but not limited to) insulin dependent diabetes, severe heart disease, severe lung disease, severe liver disease, severe kidney disease, auto immune diseases, severe gastrointestinal diseases, and uncontrolled hypertension.
    • Alcohol or drug abuse and psychiatric conditions that in the opinion of the investigator would preclude compliance with the trial or interpretation of safety or endpoint data.
    • Impaired immune function or chronic infections including (but not limited to) HIV, hepatitis B or C; organ transplant; cancer; current and/or expected receipt of chemotherapy, radiation therapy or any other cytotoxic or immunosuppressive therapy [i.e. more than 10 mg of prednisone given daily or on alternative days for 2 weeks or more in the past 3 months*; receipt of high-dose inhaled steroids is also an exclusion criteria (nasal and topical steroids are allowed.)], congenital immunodeficiency, anatomical or functional asplenia.
    • Pregnancy or breast feeding
  4. Conditions that could affect the safety of the volunteers such as:

    • Severe reactions to prior vaccination with TIV, including anaphylaxis.
    • History of Guillain Barré syndrome
    • History of bleeding disorders
    • Any allergy to any component of the vaccine including egg allergy.
  5. Volunteers with any acute illness, including any fever (> 100.4 F [> 38.0C], regardless of the route) within 3 days prior to study entry *.
  6. Social, occupational, or any other condition that in the opinion of the investigator might interfere with compliance with the study and vaccine evaluation.

    • Note:

An individual who initially is excluded from study participation based on one or more of the time-limited exclusion criteria (e.g., acute illness, receipt or expected receipt of live or inactivated vaccines ) may be reconsidered for enrollment once the condition has resolved as long as the subject continues to meet all other entry criteria.

Subjects receiving > 10 mg/day of prednisone or its equivalent daily or on alternate days for more than 2 weeks may enter the study after therapy has been discontinued for more than 3 months.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01232868

Locations
United States, Georgia
Hope Clinic of the Emory Vaccine Center
Decatur, Georgia, United States, 30030
Sponsors and Collaborators
Emory University
Investigators
Principal Investigator: Nadine Rouphael, MD Emory University
  More Information

No publications provided

Responsible Party: Nadine Rouphael, MD, Emory University
ClinicalTrials.gov Identifier: NCT01232868     History of Changes
Other Study ID Numbers: IRB00046787, NIH, VAX-001
Study First Received: October 23, 2010
Last Updated: May 29, 2014
Health Authority: United States: Federal Government

Keywords provided by Emory University:
Innate immunity
Adaptive immunity
Slu shot
Elderly

Additional relevant MeSH terms:
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on October 19, 2014